Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 -- Myriad Genetics, Inc., a leader in... -Today at 07:06 am- MarketScreener
Source: marketscreener.com